COMMUNIQUÉS West-GlobeNewswire

Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
14/05/2026
LEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
14/05/2026
MONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular [...]
Easy Environmental Solutions & Terreplenish® Show Outstanding Yield Increases & Offer Alternative To Petroleum-Based Fertilizers
14/05/2026
Terreplenish® leads the way as company responds to worldwide nitrogen shortage MANKATO, Minn., May 14, 2026 (GLOBE NEWSWIRE) -- Easy Environmental Solutions, Inc. (OTC: EZES) continues to offer a true solution to the [...]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform
14/05/2026
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic [...]
Administrative Experience Emerges as Key Pressure Point for Self-Funded Plans, Brighton Health Plan Solutions Survey Finds
14/05/2026
New report shows employee satisfaction remains high, but trust can break down when administrative friction gets in the way NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Self-funded health plans are working for many health [...]
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
14/05/2026
—New C linical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Additional Benefit in PSC [...]
CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy
14/05/2026
MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program
14/05/2026
Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep and durable MRD- [...]
Sonablate Launches SONA FUSION Global Registry to Advance Precision Sound Medicine and Define Future Standards in Focal Therapy
14/05/2026
First multinational initiative dedicated to long-term HIFU outcomes in prostate cancer and BPH aims to help close the evidence gap in incision-free prostate care CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- [...]
SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Developing Distinct Next-Gen GLP-1 Built Around Novel Peptide
14/05/2026
Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising. NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) [...]
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
14/05/2026
Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026 Announced purpose-built [...]
Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans
14/05/2026
Cena opens up about his experience living with Demodex blepharitis, a common eyelid disease caused by microscopic mites that live in and around the eyelashes This common and often overlooked condition is characterized [...]
Kyverna Therapeutics to Present at Upcoming Investor Conferences
14/05/2026
EMERYVILLE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases [...]
Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards
14/05/2026
Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Award Winner PARAMUS, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics ( [...]
20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026
14/05/2026
GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (“20/20”) (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention [...]
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
14/05/2026
BOCA RATON, FL, May 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced that the U.S. Food and Drug Administration (FDA [...]
Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
14/05/2026
Secured strategic financing vehicle for up to $40 million Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory Acute Myeloid [...]
Biogen Completes Acquisition of Apellis Pharmaceuticals
14/05/2026
CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a leader in advancing [...]
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
14/05/2026
~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK ® Demand in April 2026 ~ ~ Initiated Third [...]

Pages